City Therapeutics Inc.

CTY | NASDAQ

Price Alert Chart Builder DCF Calculator

$20.71

-$1.43 (-6.46%)

At close: Oct 30, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-6.46%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

38.2

+8.0 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #572/1028 (Top 56%)

Full Analysis

Key Statistics

Market Data

Market Cap $201.35M

1D Range

20.46 22.26

52W Range

20.43 22.72

Valuation (TTM)

PE -

PB 0.02

EV/EBITDA 1.36

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $0.00

Cash Flow

FCF Yield 1076.3%

SBC Adj. FCF Yield 1063.3%

SBC Impact -1.2%

Margins

Gross Margin 70.1%

Operating Margin 43.6%

FCF Margin 33.4%

Growth (CAGR)

Revenue 3Y | 5Y -9.4% | -6.0%

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y 22.5% | 6.9%

Returns

ROA 8.7%

ROE 18.3%

ROIC 11.4%

Financial Health

Net Debt

$4.66B

Current Ratio 0.73

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, ...

Sector Healthcare

Industry Biotechnology

Employees 75

IPO Date Oct 16, 2026

Website www.citytx.com

Fiscal Year n/a

Full Company Profile

Latest News

14 days ago · globenewswire.com

City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Addition

16 days ago · seekingalpha.com

U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings

Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research is expected to for one company in the week ahead, and four lock-up periods will be expiring.

18 days ago · globenewswire.com

City Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public offering of 11,111,111 shares of its common stock at a public offering price of $18.00 per share.

24 days ago · reuters.com

City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push

City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech ‌companies press ahead with listings despite market uncertainty.

1 month ago · seekingalpha.com

City Therapeutics, RNAi Treatment Developer, Files For IPO

City Therapeutics is advancing next-generation RNAi therapeutics, with its lead program CITY-FXI targeting thrombosis and showing promising early Phase 1 trial results. CTY boasts significant big pharma collaborations, a strong investor syndicate, and experienced leadership, positioning it as a high-quality biopharma IPO candidate. IPO proceeds will fund CITY-FXI clinical trials, advance additional pipeline assets, and support platform development, with a typical 18-month cash runway targeted.